Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients

Abstract

Intrathecal immunoglobulin synthesis in an oligoclonal pattern is the most common immunologic abnormality detected in MS patients. Various treatments, such as immunomodulators and immunosuppressors, have not been found to modify it. Natalizumab hinders migration of encephalitogenic T-cells into the central nervous system (CNS), reducing inflammatory response. Its impact on CSF oligoclonal bands (OCBs) has not been demonstrated. This report describes its effect in four out of six patients with multiple sclerosis after a mean of 10 infusions: the CSF was negative for OCBs at the second lumbar puncture. In conclusion, natalizumab treatment can reduce CSF OCBs to undetectable levels, although the clinical significance of this observation is not yet known.

Keywords

cerebrospinal fluid multiple sclerosis natalizumab therapy oligoclonal bands

Get full access to this article

View all access options for this article.

References

Ramagopalan

Dobson

Meier

Giovannoni

. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010; 9: 727–739.

Antel

Bar-Or

. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol 2006; 180: 3–8.

Freedman

Thompson

Deisenhammer

Giovannoni

Grimsley

Keir

. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Arch Neurol 2005; 62: 865–870.

Correale

Molinas

MMB

. Oligoclonal bands and antibody responses in multiple sclerosis. J Neurol 2002; 249: 375–389.

Rudick

Cookfair

Simonian

Ransohoff

Richert

Jacobs

. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. J Neuroimmunol 1999; 93: 8–14.

Saiz

Carreras

Berenguer

Yagüe

Martínez

Marín

. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 2001; 56: 1084–1089.

Piccio

Naismith

Trinkaus

Klein

Parks

Lyons

. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67: 707–714.

Niino

Bodner

Simard

Alatab

Gano

Kim

. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59: 748–754.

Damasceno

von Glehn

Martinez

Longhini

Deus-Silva

Brandão

. Early onset of natalizumab-related progressive multifocal leukoencephalopathy. Mult Scler 2011; 00: 1–3 (accessed 07 September 2011).

10.

Reiber

Ungefehr

Jacobi

. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998; 4: 111–117.

11.

Knowles

Luxton

Hand

Gardner

Brown

DWG

. The JC virus antibody response in serum and cerebrospinal fluid in progressive multifocal leukoencephalopathy. Clin Diagn Virol 1995; 2: 183–194.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.62 MB